A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers

被引:132
|
作者
Tang, XLC
Pikal, MJ
Taylor, LS [1 ]
机构
[1] Astra Zeneca R&D Molndal, Pharmaceut & Analyt R&D, Solid State Anal, S-43183 Molndal, Sweden
[2] Univ Connecticut, Sch Pharm, Storrs, CT 06296 USA
关键词
crystalline; amorphous; hydrogen bonding; vibrational spectroscopy;
D O I
10.1023/A:1015147729564
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To gain insight into the molecular structure of amorphous compounds by investigating hydrogen bonding patterns and strength in a series of structurally related compounds. Seven 1,4-dihydro- pyridine calcium channel blockers were evaluated. Methods. FT-Raman and FT-infrared spectra of the compounds in the crystalline and amorphous states were obtained. Results. For crystalline compounds, the position of the NH vibration varied considerably, indicating that the strength of hydrogen bonding differs between the different compounds in agreement with published single crystal X-ray data. For the amorphous phases, the NH vibration occurred at approximately the same position for all compounds, suggesting a uniform average hydrogen bonding strength. Somewhat surprisingly, for some compounds, the average hydrogen bond strength in the amorphous state was found to be greater than in the crystalline compound, although for others, it was weaker as anticipated. Hydrogen bonding patterns (acceptor group) varied between the crystalline compounds, but were remarkably consistent in the amorphous compounds; thus the acceptor group in the amorphous phase is not necessarily the same as in the crystalline counterpart. Conclusions. Hydrogen bond patterns and strength within a group of chemically related amorphous compounds were found to be very similar, but were different from those in the equivalent group of crystalline substances.
引用
收藏
页码:477 / 483
页数:7
相关论文
共 50 条
  • [41] Overlapping selectivity of neurotoxin and dihydropyridine calcium channel blockers in cerebellar granule neurones
    Burley, JR
    Dolphin, AC
    NEUROPHARMACOLOGY, 2000, 39 (10) : 1740 - 1755
  • [42] Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation
    Natale, Francesco
    Cirillo, Chiara
    Granato, Chiara
    Concilio, Claudia
    Siciliano, Alessandro
    Credendino, Maria
    Aronne, Luigi
    Calabro, Paolo
    Russo, Maria G.
    Calabro, Raffaele
    HYPERTENSION RESEARCH, 2011, 34 (06) : 790 - 791
  • [43] Angioedema associated with the use of dihydropyridine calcium channel blockers-A case series
    Manzano, Jose Manuel Martinez
    Lo, Kevin Bryan
    Jarrett, Simone A.
    Chiang, Brenda
    Azmaiparashvili, Zurab
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (02) : 228 - 229
  • [44] The efficacy and safety of dihydropyridine calcium channel blockers in hypertensive patients: amlodipine place
    Lebedeva, M. V.
    Beketov, V. D.
    Maltsev, N. V.
    Safarova, M. E.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2013, 9 (01) : 86 - 89
  • [45] AN ANTIBODY TO DIHYDROPYRIDINE CALCIUM ENTRY BLOCKERS - A COMPARISON WITH THE CALCIUM-CHANNEL RECEPTOR IN SKELETAL-MUSCLE
    THAYER, SA
    PHAM, DH
    SCHULTZ, CM
    MINASKANIAN, G
    FAIRHURST, AS
    BIOCHEMICAL PHARMACOLOGY, 1986, 35 (24) : 4479 - 4485
  • [46] Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers
    von Vigier, RO
    Fossali, E
    Edefonti, A
    Vogt, B
    Bianchetti, MG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (03) : 334 - 335
  • [47] NEGATIVE-ION MASS-SPECTRA OF DIHYDROPYRIDINE CALCIUM-CHANNEL BLOCKERS
    EHRHARDT, JD
    ZIEGLER, JM
    BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1988, 15 (10): : 525 - 528
  • [48] Photochemical stabilities of some dihydropyridine calcium-channel blockers in powdered pharmaceutical tablets
    Kawabe, Yuki
    Nakamura, Haruyuki
    Hino, Eri
    Suzuki, Shigeo
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 47 (03) : 618 - 624
  • [49] Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers
    Zhang, Di
    Huang, Qi-Fang
    Sheng, Chang-Sheng
    Li, Yan
    Wang, Ji-Guang
    BLOOD PRESSURE, 2021, 30 (06) : 395 - 402
  • [50] Two carbamoyl-substituted dihydropyrimidines: potential mimics of dihydropyridine calcium channel blockers
    Ravikumar, K
    Sridhar, B
    ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 2005, 61 : O41 - O44